DV
Dividend Vision

CABA — Cabaletta Bio Inc

Cabaletta Bio Inc (CABA)

Total return is -72.5% over the past 6.8 years, 256.3 points behind SPY at 183.8%. Its deepest 1-year drawdown was 43.5%.

Cabaletta Bio is a clinical-stage biotechnology company focused on discovering and developing engineered T cell therapies for autoimmune diseases, with its lead candidate resecabtagene autoleucel currently in Phase 1/2 trials for conditions including lupus, multiple sclerosis, myositis, and pemphigus vulgaris. The company does not currently distribute dividends or other income to shareholders. Cabaletta Bio appeals primarily to investors seeking exposure to early-stage biotech development with no expectation of current income, as the company is pre-revenue and capital-intensive.

CABA key facts

Asset type
Stock
Asset class
Equity
Inception date
10/25/2019
Last close
$2.75
Market cap
$461,445,056
Average volume
2352224.0
Beta
3.257
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.90